EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSPEMG00000013238
Gene Symbol: ATP1A2
3 Cross references
205 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSPEMG00000011099
Gene Symbol: ATP1A3
3 Cross references
134 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSPEMG00000009297
Gene Symbol: ATP1B2
3 Cross references
274 Possible Orthologues:

Atpase, Na+/k+ Transporting, Beta 1 Polypeptide

Ensembl ID : ENSPEMG00000020031
Gene Symbol: ATP1B1
1 Cross references
294 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSPEMG00000022407
Gene Symbol: ATR
3 Cross references
206 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSPEMG00000008484
Gene Symbol: AXL
3 Cross references
197 Possible Orthologues:

B Cell Leukemia/lymphoma 2

Ensembl ID : ENSPEMG00000023121
Gene Symbol: BCL2
1 Cross references
227 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSPEMG00000025383
Gene Symbol: BCL2L1
3 Cross references
287 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSPEMG00000015772
Gene Symbol: BCR
1 Cross references
274 Possible Orthologues:

Braf Transforming Gene

Ensembl ID : ENSPEMG00000001337
Gene Symbol: BRAF
1 Cross references
220 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSPEMG00000019614
Gene Symbol: BTK
3 Cross references
206 Possible Orthologues:

C-C Chemokine Receptor 1-Like Protein 1

Ensembl ID : ENSPEMG00000002387
Gene Symbol: LOC102921992
3 Cross references
290 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).